COST-EFFECTIVENESS ANALYSIS OF EXTENDED THROMBOPROPHYLAXIS IN HIP FRACTURE: FONDAPARINUX VERSUS ENOXAPARIN

We compared the cost-effetiveness relationship of 2 5 mg fondaparinux daily administered subcutaneous for four weeks versus 40 mg enoxaparin daily administered subcutaneously for six weeks, fir preventing the venous thromboembolic disease in patients undergoing hip fracture surgery We have chosen a simplified decision analysis model with a 5-year timeframe and a 5% discount rate The sensitivity analysis (univariate, bivariate and trivariate) has been performed fir the variables. both cost and thromboemboic events, that could determine the choice of alternatives. The average cost per patient was (sic) 1,507 fir enoxaparin and (sic) 583 for fondaparinux Nonetheless, the cost-efficiency ratio for enoxaaparin was (sic) 1531 and fondaparinux (sic) 1,881 61 per symptomatic thromboembolic event. The sensitivity analysis confirmed the choice fondaparinux as a more cost-effective thromboprophylactic alternative than enoxaparin. We conclude that the dosage patterns. data and assumptions in the model show a higher cost-efficiency relationship fir fondaparinux than enoxaparin in the treatment of extended thromboprophylaxis for the venous thromboembolic disease after hip fracture surgery